Abbott has begun a Japanese clinical study of its Absorb Bioresorbable Vascular Scaffold, a drug-eluting stent that dissolves in the cardiac vessel slowly to eventually bring the vessel back to its normal functioning state. The trial, which will involve about 400 patients with coronary artery disease, will back the company's pursuit for regulatory approval in Japan.

Related Summaries